119610.KQ
Interojo Inc.
KOE · Healthcare · Medical - Instruments & Supplies · KR
KRW 13,530.00
−1.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 124.2B | 118.5B | 115.8B | 119.3B | 117.8B |
| Cost of Revenue | 75.3B | 77.7B | 80.3B | 82.7B | 64.3B |
| Gross Profit | 48.8B | 40.7B | 35.5B | 36.6B | 53.6B |
| Operating Expenses | |||||
| R&D Expense | 1.8B | 3.9B | 5.5B | 4.4B | 5.1B |
| SG&A Expense | 10.0B | 11.5B | 12.5B | 13.5B | 22.5B |
| General & Admin Expense | 1.3B | 1.6B | 888.8M | 1.3B | 556.2M |
| Selling & Marketing Expense | 8.7B | 9.9B | 11.6B | 12.3B | 12.2B |
| Other Expenses | 14.6B | 5.9B | 11.7B | 13.5B | 1.8B |
| Total Operating Expenses | 25.7B | 21.2B | 29.7B | 31.4B | 29.4B |
| Cost and Expenses | 101.1B | 99.1B | 110.0B | 114.1B | 93.6B |
| Operating Income (EBIT) | 23.2B | 19.5B | 5.8B | 5.2B | 24.2B |
| Non-Operating | |||||
| Interest Income | 481.1M | 446.2M | 268.5M | 405.0M | 223.9M |
| Interest Expense | 2.6B | 2.6B | 4.7B | 2.8B | 1.2B |
| Net Interest Income | (2.1B) | (2.1B) | (4.4B) | (2.4B) | (1.0B) |
| Other Non-Op Income/Expense | (1.1B) | (4.1B) | (4.1B) | (2.2B) | (2.6B) |
| Non-Operating Income (excl Interest) | 258.5M | — | 798.6M | (685.6M) | 1.3B |
| EBT (Pre-Tax Income) | 22.1B | 15.4B | 1.7B | 3.0B | 21.6B |
| Income Tax Expense | 4.3B | 2.5B | 1.5B | 111.7M | 3.0B |
| Bottom Line | |||||
| Net Income | 17.8B | 13.0B | 184.3M | 3.2B | 18.6B |
| Earnings from Cont. Ops | 17.8B | 12.9B | 179.6M | 3.1B | 18.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 17.8B | 13.0B | 184.3M | 3.2B | 18.6B |
| Per Share | |||||
| Basic EPS | ₩1,563 | ₩1,139 | ₩15 | ₩253 | ₩1,472 |
| Diluted EPS | ₩1,563 | ₩1,139 | ₩15 | ₩253 | ₩1,469 |
| Revenue Per Share | ₩10,896 | ₩10,385 | ₩9,245 | ₩9,541 | ₩9,302 |
| Shares | |||||
| Basic Shares Outstanding | 11.4M | 11.4M | 12.5M | 12.5M | 12.7M |
| Diluted Shares Outstanding | 11.4M | 11.4M | 12.5M | 12.5M | 13.0M |
| Profitability Metrics | |||||
| EBITDA | 33.1B | 29.5B | 15.2B | 28.8B | 39.1B |
| D&A | 10.1B | 10.0B | 10.2B | 9.7B | 9.3B |
| EBIT | 23.0B | 19.5B | 5.0B | 5.2B | 29.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026